In another Asiatic cohort comprising 30 patients with SCLC (20 in extended- and 10 in limited-stage), 33% (n = 10) of tumors had molecular alterations, including six EGFR, two PTEN, one KRAS, and one PIK3CA mutations. This evidence concerns the gene KRAS and small cell lung carcinoma.